Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children.

Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children.

Drug Metab Dispos. 2016 Apr 6;

Authors: Dinh JC, Pearce RE, Van Haandel L, Gaedigk A, Leeder JS

Abstract
Atomoxetine (ATX) is a second-line non-stimulant medication used to control symptoms of attention deficit hyperactivity disorder (ADHD). Inconsistent therapeutic efficacy has been reported with ATX, which may be related to variable CYP2D6-mediated drug clearance. We characterized ATX metabolism in a panel of human liver samples as a basis for a bottom-up PBPK model to aid in ATX exposure prediction and control. Km, Vmax, and Clintvalues in pooled human liver microsomes (HLMs) were 2.4 μM, 479 pmol/min/mg protein, and 202 μL/min/mg protein respectively. Km, Vmax, and Clintvalues from single-donor HLMs ranged from 0.93 – 79.2 μM, 20.0 – 1600 pmol/min/mg protein, and 0.3 – 936 μL/min/mg protein. All kinetic parameters were calculated from 4′-OH-ATX formation. The presence of at least one functional CYP2D6 allele appeared to influence Clint in HLMs. CYP2E1 and CYP3A contributed to 4′-OH-ATX formation in livers with CYP2D6 intermediate and poor metabolizer status. In HLMs with lower CYP2D6 activity levels, 2′-methyl-OH-ATX formation became a more predominant pathway of metabolism, which appeared to be catalyzed by CYP2B6. An ATX screen at clinically relevant plasma concentrations was conducted in a panel of pediatric HLM (n = 116) samples by evaluating primary metabolites. Competing pathways of ATX metabolism (NDM-ATX and 2′-methyl-OH-ATX formation) had increasing importance in livers with lesser CYP2D6 activity. However, overall ATX clearance was still compromised in pediatric HLMs with lower CYP2D6 activity. Modeling ATX exposure to individualize therapy would require incorporation of CYP2D6 activity as well as an understanding of competing pathways, particularly for individuals with lower CYP2D6 activity.

PMID: 27052878 [PubMed – as supplied by publisher]

via http://www.ncbi.nlm.nih.gov/pubmed/27052878?dopt=Abstract